target audience: TECH BUYER  Publication date: Dec 2022 - Document type: IDC MarketScape - Doc  Document number: # US48061622

IDC MarketScape: Worldwide Life Science R&D Pharmacovigilance Solutions 2022 Vendor Assessment

By:  Nimita Limaye Loading


Get More

When you purchase this document, the purchase price can be applied to the cost of an annual subscription, giving you access to more research for your investment.

Related Links


This IDC study focuses on a combination of PV technology solutions and consulting services. This IDC MarketScape provides a qualitative and quantitative assessment based on criteria that should be important to life science companies when considering the selection of a strategic PV solution provider to help provide guidance for strategic, operational, and tactical transformation issues within the PV space, as well as technology platforms, and build capabilities. This is the second time that an IDC MarketScape assessment of PV solutions for life science R&D has been performed.

Dr. Nimita Limaye, research VP, Life Science R&D Strategy and Technology at IDC, noted, "Pharmacovigilance has gained significant importance and a more visible public profile post the COVID-19 pandemic. The surge in the volume of cases, the need to accelerate innovation while ensuring patient safety, and the need to address the distrust that the pharma industry experienced during the pandemic, all call for a focused effort toward implementing a forward-looking PV strategy and adopting technology solutions that leverage cognitive automation, build compliance, drive efficiency, ensure patient safety, and build transparency and trust."


Do you have questions about this document
or available subscriptions?